Advertisement
Advertisement
KYMR
Kymera Therapeutics, Inc. Common Stock
80.61
USDSponsored
-0.04
-0.05%
May 21, 16:00 UTC -4
Closed
After-Market
80.62
+0.01
+0.01%
KYMR Earnings Reports
Positive Surprise Ratio
KYMR beat 7 of 23 last estimates.
30%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$31.21M
/-$0.68
Implied change from Q1 26 (Revenue/ EPS)
-9.19%
/-4.23%
Implied change from Q2 25 (Revenue/ EPS)
+171.93%
/-28.42%
Kymera Therapeutics, Inc. Common Stock earnings per share and revenue
On Apr 30, 2026, KYMR reported earnings of -0.71 USD per share (EPS) for Q1 26, beating the estimate of -0.89 USD, resulting in a 21.05% surprise. Revenue reached 34.37 million, compared to an expected 8.79 million, with a 291.12% difference. The market reacted with a -0.54% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -0.68 USD, with revenue projected to reach 31.21 million USD, implying an decrease of -4.23% EPS, and decrease of -9.19% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
TuHURA Biosciences, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-10.83%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
BioXcel Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.54
Surprise
-9.16%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were Kymera Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Kymera Therapeutics, Inc. Common Stock reported EPS of -$0.71, beating estimates by 21.05%, and revenue of $34.37M, 291.12% above expectations.
How did the market react to Kymera Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -0.54%, changed from $81.51 before the earnings release to $81.07 the day after.
When is Kymera Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Kymera Therapeutics, Inc. Common Stock's next earnings report?
Based on 13
analysts, Kymera Therapeutics, Inc. Common Stock is expected to report EPS of -$0.68 and revenue of $31.21M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement